" class="no-js "lang="en-US"> Matthew Walls - Medtech Alert
Tuesday, August 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Matthew Walls

Matthew Walls

About Matthew Walls

Related Story

Cardiovascular

 GENinCode Announces Major US Commercialisation Partnership with EVERSANA | Pharmtech Focus

GENinCode Announces Major US Commercialisation Partnership with EVERSANA

June 14 2021

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of […]

Cardiovascular

 GEN inCode Announces Major UK Collaboration | Pharmtech Focus

GEN inCode Announces Major UK Collaboration

April 28 2021

GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention […]